Experts Critique Study Linking GLP-1 Use to Breast Cancer Survival
A study published in Nature Medicine examining the association between GLP-1 receptor agonist use and breast cancer survival has drawn sharp criticism from medical experts. Dr. Mangesh Thorat of Queen Mary University of London highlighted major weaknesses, including substantial selection bias, incomplete data on key clinical variables like ER status and treatment types, and significant attrition. He argued that these flaws make it impossible to draw certain conclusions about breast cancer-specific benefits, suggesting any observed reduction in deaths is likely due metabolic effects rather than reduced recurrence. Professor Paul Pharoah from Cedars-Sinai Medical Center emphasized the limitations of the observational design, noting that causality cannot be established. He pointed out that while all-cause mortality is a robust endpoint, it may be influenced by reduced cardiovascular deaths rather than cancer outcomes. Additionally, he warned that relapse-free survival data is prone to ascertainment bias, as patients on novel therapies often receive more frequent monitoring. Both experts agreed that while GLP-1 drugs show metabolic promise, prospective clinical trials are necessary to determine their true role in cancer treatment settings.
Wire timeline
Experts Critique Study Linking GLP-1 Use to Breast Cancer Survival
A study published in Nature Medicine examining the association between GLP-1 receptor agonist use and breast cancer survival has drawn sharp criticism from medical experts. Dr. Mangesh Thorat of Queen Mary University of London highlighted major weaknesses, including substantial selection bias, incomplete data on key clinical variables like ER status and treatment types, and significant attrition. He argued that these flaws make it impossible to draw certain conclusions about breast cancer-specific benefits, suggesting any observed reduction in deaths is likely due metabolic effects rather than reduced recurrence. Professor Paul Pharoah from Cedars-Sinai Medical Center emphasized the limitations of the observational design, noting that causality cannot be established. He pointed out that while all-cause mortality is a robust endpoint, it may be influenced by reduced cardiovascular deaths rather than cancer outcomes. Additionally, he warned that relapse-free survival data is prone to ascertainment bias, as patients on novel therapies often receive more frequent monitoring. Both experts agreed that while GLP-1 drugs show metabolic promise, prospective clinical trials are necessary to determine their true role in cancer treatment settings.
Science Media Centre